Company news

Share this article:

Drug developer Depomed said it would cut about 25% of its workforce after its lead drug candidate, Gabapentin GR, failed in a late-stage clinical trial. The company had 105 full-time employees as of Dec. 31, according to a filing with the Securities and Exchange Commission.


Forest Laboratories and Microbia announced that they have entered into co-development and co-marketing deal valued at up to $330 million for Microbia's first-in-class compound linaclotide, currently being investigated for the treatment of constipation-predominant irritable bowel syndrome, chronic constipation and other gastrointestinal disorders.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.